By Karen Blum
The limited treatment options and poor outcomes in glioblastoma remain a major roadblock for this debilitating malignancy, according to a leading oncologist.
The underpowered state of glioblastoma therapy “underscores the importance of identifying innovative therapies for this population,” said Prianka Singh, PharmD, the senior manager of oncology and U.S. health economics and outcomes research for Bristol-Myers Squibb (BMS), which released a study documenting these